Form 4: Cytokinetics EVP Fady Malik Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on February 4, 2025.
Summary
- On February 4, 2025, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc. (CYTK), executed transactions involving the company's stock.
- Malik exercised non-qualified stock options to acquire 2,000 shares of common stock at a price of $10.60 per share.
- Simultaneously, Malik sold 2,000 shares of common stock at a price of $48.06 per share.
- Following these transactions, Malik directly owns 116,071 shares of Cytokinetics Inc.
- Malik also holds 35,105 non-qualified stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction disclosure. No specific positive or negative implications can be derived without further context.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Key Dates
| Date | Description |
|---|---|
| 03/28/2017 | Date the Non-Qualified Stock Option was granted. |
| 02/28/2027 | Expiration date of the Non-Qualified Stock Option. |
| 02/04/2025 | Date of stock option exercise and sale. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.